Anti-PD-1 treated mice showed a lower penetrance of AML infiltration in the liver, the major site of infiltration of this disease in unconditioned immunocompetent mice, with fewer tumors per liver and a trend to reduced tumor area (Fig. 4G). This evidence concerns the gene PDCD1 and neoplasm.